IBDEI0M2 ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10824,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,10825,0)
 ;;=250.02^^70^706^5
 ;;^UTILITY(U,$J,358.3,10825,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10825,1,3,0)
 ;;=3^250.02
 ;;^UTILITY(U,$J,358.3,10825,1,4,0)
 ;;=4^DIAB MEL W/O COMP, TYPE II UNCONT
 ;;^UTILITY(U,$J,358.3,10825,2)
 ;;=^295704
 ;;^UTILITY(U,$J,358.3,10826,0)
 ;;=272.4^^70^706^9
 ;;^UTILITY(U,$J,358.3,10826,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10826,1,3,0)
 ;;=3^272.4
 ;;^UTILITY(U,$J,358.3,10826,1,4,0)
 ;;=4^HYPERLIPIDEMIA
 ;;^UTILITY(U,$J,358.3,10826,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,10827,0)
 ;;=244.9^^70^706^10
 ;;^UTILITY(U,$J,358.3,10827,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10827,1,3,0)
 ;;=3^244.9
 ;;^UTILITY(U,$J,358.3,10827,1,4,0)
 ;;=4^HYPOTHYROIDISM
 ;;^UTILITY(U,$J,358.3,10827,2)
 ;;=^123752
 ;;^UTILITY(U,$J,358.3,10828,0)
 ;;=250.01^^70^706^4
 ;;^UTILITY(U,$J,358.3,10828,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10828,1,3,0)
 ;;=3^250.01
 ;;^UTILITY(U,$J,358.3,10828,1,4,0)
 ;;=4^DIAB MEL W/O COMP, TYPE I
 ;;^UTILITY(U,$J,358.3,10828,2)
 ;;=^33586
 ;;^UTILITY(U,$J,358.3,10829,0)
 ;;=278.01^^70^706^11
 ;;^UTILITY(U,$J,358.3,10829,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10829,1,3,0)
 ;;=3^278.01
 ;;^UTILITY(U,$J,358.3,10829,1,4,0)
 ;;=4^OBESITY, MORBID
 ;;^UTILITY(U,$J,358.3,10829,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,10830,0)
 ;;=286.59^^70^706^7
 ;;^UTILITY(U,$J,358.3,10830,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10830,1,3,0)
 ;;=3^286.59
 ;;^UTILITY(U,$J,358.3,10830,1,4,0)
 ;;=4^HEMOR D/O DUE TO CIRC ANTICOAG
 ;;^UTILITY(U,$J,358.3,10830,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,10831,0)
 ;;=268.9^^70^706^12
 ;;^UTILITY(U,$J,358.3,10831,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10831,1,3,0)
 ;;=3^268.9
 ;;^UTILITY(U,$J,358.3,10831,1,4,0)
 ;;=4^VITAMIN D DEFICIENCY NOS
 ;;^UTILITY(U,$J,358.3,10831,2)
 ;;=^126968
 ;;^UTILITY(U,$J,358.3,10832,0)
 ;;=790.29^^70^706^8
 ;;^UTILITY(U,$J,358.3,10832,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10832,1,3,0)
 ;;=3^790.29
 ;;^UTILITY(U,$J,358.3,10832,1,4,0)
 ;;=4^HYPERGLYCEMIA
 ;;^UTILITY(U,$J,358.3,10832,2)
 ;;=^329955
 ;;^UTILITY(U,$J,358.3,10833,0)
 ;;=389.9^^70^707^7
 ;;^UTILITY(U,$J,358.3,10833,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10833,1,3,0)
 ;;=3^389.9
 ;;^UTILITY(U,$J,358.3,10833,1,4,0)
 ;;=4^HEARING LOSS
 ;;^UTILITY(U,$J,358.3,10833,2)
 ;;=^54552
 ;;^UTILITY(U,$J,358.3,10834,0)
 ;;=380.4^^70^707^8
 ;;^UTILITY(U,$J,358.3,10834,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10834,1,3,0)
 ;;=3^380.4
 ;;^UTILITY(U,$J,358.3,10834,1,4,0)
 ;;=4^IMPACTED CERUMEN
 ;;^UTILITY(U,$J,358.3,10834,2)
 ;;=^62061
 ;;^UTILITY(U,$J,358.3,10835,0)
 ;;=382.9^^70^707^9
 ;;^UTILITY(U,$J,358.3,10835,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10835,1,3,0)
 ;;=3^382.9
 ;;^UTILITY(U,$J,358.3,10835,1,4,0)
 ;;=4^OTITIS MEDIA
 ;;^UTILITY(U,$J,358.3,10835,2)
 ;;=^123967
 ;;^UTILITY(U,$J,358.3,10836,0)
 ;;=365.11^^70^707^5
 ;;^UTILITY(U,$J,358.3,10836,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10836,1,3,0)
 ;;=3^365.11
 ;;^UTILITY(U,$J,358.3,10836,1,4,0)
 ;;=4^GLAUCOMA,PRIMARY OPEN ANGLE
 ;;^UTILITY(U,$J,358.3,10836,2)
 ;;=^51203
 ;;^UTILITY(U,$J,358.3,10837,0)
 ;;=372.72^^70^707^11
 ;;^UTILITY(U,$J,358.3,10837,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10837,1,3,0)
 ;;=3^372.72
 ;;^UTILITY(U,$J,358.3,10837,1,4,0)
 ;;=4^SUBCONJUNCTIVAL HEMORRHAGE
 ;;^UTILITY(U,$J,358.3,10837,2)
 ;;=^27538
 ;;^UTILITY(U,$J,358.3,10838,0)
 ;;=365.70^^70^707^1
 ;;^UTILITY(U,$J,358.3,10838,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10838,1,3,0)
 ;;=3^365.70
